APCM Wealth Management for Individuals bought a new stake in Shire PLC (NASDAQ:SHPG) during the 4th quarter, HoldingsChannel.com reports. The firm bought 3,170 shares of the biopharmaceutical company’s stock, valued at approximately $491,000. Shire comprises approximately 0.2% of APCM Wealth Management for Individuals’ holdings, making the stock its 28th biggest holding.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Commerzbank Aktiengesellschaft FI increased its holdings in shares of Shire by 22.1% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 2,073 shares of the biopharmaceutical company’s stock valued at $322,000 after purchasing an additional 375 shares during the last quarter. ETRADE Capital Management LLC increased its holdings in shares of Shire by 6.9% in the fourth quarter. ETRADE Capital Management LLC now owns 7,212 shares of the biopharmaceutical company’s stock valued at $1,119,000 after purchasing an additional 466 shares during the last quarter. Hills Bank & Trust Co. increased its holdings in shares of Shire by 12.2% in the fourth quarter. Hills Bank & Trust Co. now owns 5,960 shares of the biopharmaceutical company’s stock valued at $924,000 after purchasing an additional 647 shares during the last quarter. Putnam FL Investment Management Co. increased its holdings in shares of Shire by 9.9% in the fourth quarter. Putnam FL Investment Management Co. now owns 7,442 shares of the biopharmaceutical company’s stock valued at $1,154,000 after purchasing an additional 670 shares during the last quarter. Finally, SeaCrest Wealth Management LLC acquired a new stake in shares of Shire in the fourth quarter valued at approximately $107,000. Institutional investors and hedge funds own 19.59% of the company’s stock.
Shares of Shire PLC (SHPG) opened at $129.29 on Tuesday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.55 and a current ratio of 0.97. The stock has a market capitalization of $40,482.99, a price-to-earnings ratio of 9.20, a price-to-earnings-growth ratio of 0.77 and a beta of 1.44. Shire PLC has a one year low of $123.73 and a one year high of $192.15.
Shire (NASDAQ:SHPG) last posted its earnings results on Wednesday, February 14th. The biopharmaceutical company reported $3.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.86 by $0.12. The company had revenue of $4.14 billion during the quarter. Shire had a return on equity of 14.19% and a net margin of 28.17%. Shire’s revenue was up 8.9% compared to the same quarter last year. During the same period last year, the business earned $3.37 EPS. equities analysts expect that Shire PLC will post 15.23 EPS for the current year.
The company also recently disclosed a semiannual dividend, which will be paid on Tuesday, April 24th. Stockholders of record on Friday, March 9th will be paid a $0.8937 dividend. The ex-dividend date of this dividend is Thursday, March 8th. This is a boost from Shire’s previous semiannual dividend of $0.15. This represents a dividend yield of 1.33%. Shire’s payout ratio is presently 7.47%.
Several research firms recently commented on SHPG. Piper Jaffray Companies reaffirmed a “hold” rating on shares of Shire in a report on Wednesday, January 3rd. Cantor Fitzgerald set a $222.00 price target on Shire and gave the company a “buy” rating in a report on Wednesday, January 3rd. Liberum Capital reaffirmed a “hold” rating on shares of Shire in a report on Wednesday, December 20th. Cowen set a $225.00 price target on Shire and gave the company a “buy” rating in a report on Friday, January 5th. Finally, Zacks Investment Research cut Shire from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. One research analyst has rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $204.00.
WARNING: This piece was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/03/20/3170-shares-in-shire-plc-shpg-acquired-by-apcm-wealth-management-for-individuals.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.